Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Nutriband Inc (NTRB)

Nutriband Inc (NTRB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 26,633
  • Shares Outstanding, K 7,833
  • Annual Sales, $ 2,080 K
  • Annual Income, $ -4,480 K
  • 60-Month Beta 0.97
  • Price/Sales 13.11
  • Price/Cash Flow N/A
  • Price/Book 4.44
Trade NTRB with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 01/31/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.21
  • Growth Rate Est. (year over year) +475,814.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.20 +6.25%
on 04/23/24
4.64 -26.72%
on 04/08/24
-1.17 (-25.60%)
since 04/05/24
3-Month
2.22 +53.15%
on 03/15/24
5.93 -42.64%
on 03/28/24
+0.85 (+33.33%)
since 02/07/24
52-Week
1.53 +122.22%
on 10/27/23
5.93 -42.64%
on 03/28/24
-0.18 (-5.03%)
since 05/05/23

Most Recent Stories

More News
Nutriband’s (NASDAQ: NTRB) Transdermal Patch with Abuse-Deterrent Tech Funded to Seek FDA Approval

Fentanyl addiction continues to devastate communities, with current treatment options facing limitations. However, as often happens in healthcare, innovation breeds hope with a new option on the horizon...

NTRB : 3.39 (-0.29%)
Nutriband (NASDAQ: NTRB) Engages IBN for Corporate Communications Expertise

Nutriband (NASDAQ: NTRB, NTRBW), a pharmaceutical company with a special focus on transdermal technologies, today announced that it has selected IBN , a multifaceted financial news and publishing company...

NTRB : 3.39 (-0.29%)
NTRBW : 0.5500 (unch)
Nutriband (NASDAQ: NTRB) Closes $8.4M Private Placement

Nutriband (NASDAQ: NTRB, NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that it has closed an $8.4 million private placement to fund the...

NTRB : 3.39 (-0.29%)
NTRBW : 0.5500 (unch)
Nutriband (NASDAQ: NTRB) Advances Abuse Deterrent Tech Addressing Fentanyl Epidemic

Fentanyl, a potent opioid, poses a significant problem due to its potential for abuse with a high risk of overdose – even in small quantities. Nutriband (NASDAQ: NTRB) is advancing its AVERSA(TM) technology...

NTRB : 3.39 (-0.29%)
Nutriband (NASDAQ: NTRB) Enters Private Placement Agreements to Fund Development of AVERSA Fentanyl

Nutriband (NASDAQ: NTRB), a company engaged in the development of abuse-deterrent pharmaceutical products, has entered into definitive securities purchase agreements. The agreements are for the purchase...

NTRB : 3.39 (-0.29%)
Nutriband (NASDAQ: NTRB) Is ‘One to Watch’

Nutriband (NASDAQ: NTRB) is engaged in the development of a portfolio of transdermal pharmaceutical products. The company’s AVERSA(TM) technology can be incorporated into any transdermal patch and includes...

NTRB : 3.39 (-0.29%)
Demand for Abuse Deterrent Formulation Technology Skyrocketing as Opiate Abuse is on the Rise

/PRNewswire/ -- The demand for abuse deterrent formulation technology is projected to grow due to growing misuse of drugs among the people. Growing demand for...

NTRBW : 0.5500 (unch)
CYBN : 0.3600 (-2.17%)
NTRB : 3.39 (-0.29%)
CMND : 1.4500 (+23.93%)
MNMD : 9.50 (+3.04%)
LLY : 776.74 (+1.31%)
Demand for Abuse Deterrent Formulation Technology Skyrocketing as Opiate Abuse is on the Rise

EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:CMND),(NASDAQ:MNMD),(NYSE:CYBN),(NYSE:LLY) EQNX::TICKER_END

NTRB : 3.39 (-0.29%)
NTRBW : 0.5500 (unch)
CMND : 1.4500 (+23.93%)
MNMD : 9.50 (+3.04%)
CYBN : 0.3600 (-2.17%)
LLY : 776.74 (+1.31%)
Nutriband Announces Issuance of U.S. Patent for Transdermal Abuse Deterrent Technology

Patent issuance expands U.S. patent portfolio for AVERSA™ transdermal abuse deterrent technology   Orlando, FL – September 20, 2023 – Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a developer of...

NTRB : 3.39 (-0.29%)
NTRBW : 0.5500 (unch)
U.S. Non-Farm Payrolls Due Next Week

Monday U.S. Featured Earnings HEICO Corporation (NYSE:HEI) (Q3) EPS projects for 65 cents, compared ...

HEI : 209.05 (-1.70%)
CTLT : 56.65 (+0.50%)
HTHT : 40.05 (-2.15%)
BIDU : 110.47 (-2.52%)
CRWD : 316.17 (-0.52%)
HPQ : 28.43 (+0.04%)
BF.B : 47.44 (+1.11%)
VEEV : 205.55 (+1.19%)
MDB : 356.03 (-2.64%)
AVGO : 1,303.73 (-0.50%)
LULU : 351.00 (+0.22%)
HRL : 35.17 (+1.06%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Nutriband Inc. is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. The company is engaged in developing to provide clinicians and patients with an abuse deterrent transdermal fentanyl product for use in managing chronic pain requiring opioid therapy. Nutriband...

See More

Key Turning Points

3rd Resistance Point 3.53
2nd Resistance Point 3.49
1st Resistance Point 3.44
Last Price 3.39
1st Support Level 3.35
2nd Support Level 3.31
3rd Support Level 3.26

See More

52-Week High 5.93
Fibonacci 61.8% 4.25
Fibonacci 50% 3.73
Last Price 3.39
Fibonacci 38.2% 3.21
52-Week Low 1.53

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar